245 related articles for article (PubMed ID: 11284937)
1. In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species.
Moore CB; Oakley KL; Denning DW
Clin Microbiol Infect; 2001 Jan; 7(1):11-6. PubMed ID: 11284937
[TBL] [Abstract][Full Text] [Related]
2. Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.
Cuenca-Estrella M; Mellado E; Díaz-Guerra TM; Monzón A; Rodríguez-Tudela JL
J Antimicrob Chemother; 2000 Sep; 46(3):475-7. PubMed ID: 10980178
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp.
Oakley KL; Moore CB; Denning DW
Antimicrob Agents Chemother; 1998 Oct; 42(10):2726-30. PubMed ID: 9756785
[TBL] [Abstract][Full Text] [Related]
4. Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp.
Marco F; Pfaller MA; Messer SA; Jones RN
Diagn Microbiol Infect Dis; 1998 Sep; 32(1):33-7. PubMed ID: 9791755
[TBL] [Abstract][Full Text] [Related]
5. In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents.
Pfaller MA; Messer SA; Coffman S
Antimicrob Agents Chemother; 1997 Apr; 41(4):763-6. PubMed ID: 9087485
[TBL] [Abstract][Full Text] [Related]
6. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents.
Quindós G; Carrillo-Muñoz AJ; Arévalo MP; Salgado J; Alonso-Vargas R; Rodrigo JM; Ruesga MT; Valverde A; Pemán J; Cantón E; Martín-Mazuelos E; Pontón J
Chemotherapy; 2000; 46(6):395-401. PubMed ID: 11053905
[TBL] [Abstract][Full Text] [Related]
7. Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits.
Petraitiene R; Petraitis V; Groll AH; Candelario M; Sein T; Bell A; Lyman CA; McMillian CL; Bacher J; Walsh TJ
Antimicrob Agents Chemother; 1999 Sep; 43(9):2148-55. PubMed ID: 10471556
[TBL] [Abstract][Full Text] [Related]
8. Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method.
Arévalo MP; Carrillo-Muñoz AJ; Salgado J; Cardenes D; Brió S; Quindós G; Espinel-Ingroff A
J Antimicrob Chemother; 2003 Jan; 51(1):163-6. PubMed ID: 12493803
[TBL] [Abstract][Full Text] [Related]
9. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates.
Uzun O; Kocagöz S; Cetinkaya Y; Arikan S; Unal S
Antimicrob Agents Chemother; 1997 May; 41(5):1156-7. PubMed ID: 9145888
[TBL] [Abstract][Full Text] [Related]
11. Antifungal susceptibility of 262 bloodstream yeast isolates from a mixed cancer and non-cancer patient population: is there a correlation between in-vitro resistance to fluconazole and the outcome of fungemia?
Kovacicova G; Krupova Y; Lovaszova M; Roidova A; Trupl J; Liskova A; Hanzen J; Milosovic P; Lamosova M; Macekova L; Szovenyiova Z; Purgelova A; Obertik T; Bille J; Krcmery V
J Infect Chemother; 2000 Dec; 6(4):216-21. PubMed ID: 11810569
[TBL] [Abstract][Full Text] [Related]
12. Therapies against murine Candida guilliermondii infection, relationship between in vitro antifungal pharmacodynamics and outcome.
Paredes K; Pastor FJ; Capilla J; Sutton DA; Mayayo E; Fothergill AW; Guarro J
Rev Iberoam Micol; 2015; 32(1):34-9. PubMed ID: 24594291
[TBL] [Abstract][Full Text] [Related]
13.
O'Brien B; Chaturvedi S; Chaturvedi V
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932367
[TBL] [Abstract][Full Text] [Related]
14. In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species.
Karlowsky JA; Harding GA; Zelenitsky SA; Hoban DJ; Kabani A; Balko TV; Turik M; Zhanel GG
Antimicrob Agents Chemother; 1997 Nov; 41(11):2576-8. PubMed ID: 9371373
[TBL] [Abstract][Full Text] [Related]
15. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
Takakura S; Fujihara N; Saito T; Kudo T; Iinuma Y; Ichiyama S
J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
[TBL] [Abstract][Full Text] [Related]
16. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2005 Nov; 43(11):5425-7. PubMed ID: 16272464
[TBL] [Abstract][Full Text] [Related]
17. Species and susceptibility distribution of 1062 clinical yeast isolates to azoles, echinocandins, flucytosine and amphotericin B from a multi-centre study.
Schmalreck AF; Willinger B; Haase G; Blum G; Lass-Flörl C; Fegeler W; Becker K;
Mycoses; 2012 May; 55(3):e124-37. PubMed ID: 22233267
[TBL] [Abstract][Full Text] [Related]
18. Patterns of amphotericin B killing kinetics against seven Candida species.
Cantón E; Pemán J; Gobernado M; Viudes A; Espinel-Ingroff A
Antimicrob Agents Chemother; 2004 Jul; 48(7):2477-82. PubMed ID: 15215097
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of caspofungin compared to amphotericin B, fluconazole, and itraconazole against Candida strains isolated in a Turkish University Hospital.
Arikan S; Sancak B; Hascelik G
Med Mycol; 2005 Mar; 43(2):171-8. PubMed ID: 15832560
[TBL] [Abstract][Full Text] [Related]
20. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
Oz Y; Akşit F; Kiraz N; Kiremitçi A
Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
